Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5O6GC)

• Drug Name: ONO-9054 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Glaucoma/ocular hypertension	9C61	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 50902259
  TTD Drug ID: DM5O6GC

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin F2-alpha receptor (PTGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[2]
Latanoprost	DMI5OXG	Ocular hypertension	9C61.01	Approved	[3]
BOL-303259-X	DM2EXC5	Open-angle glaucoma	9C61	Approved	[4]
Tafluprost	DMFC41K	Glaucoma/ocular hypertension	9C61	Approved	[5]
Carboprost Tromethamine	DMS3508	Abortion	JA00	Approved	[6]
Travoprost	DM20K91	Ocular hypertension	9C61.01	Approved	[7]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[8]
PGF2ALPHA-IE	DM5DAP3	Glaucoma/ocular hypertension	9C61	Phase 3	[9]
PDC-41	DM74YO8	Dysmenorrhea	GA34.3	Phase 1	[10]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[11]

Drug(s) Targeting Prostaglandin E2 receptor EP3 (PTGER3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[12]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[12]
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[2]
DG041	DMVO9WM	Peripheral vascular disease	BD4Z	Discontinued in Phase 2	[13]
GR-63799X	DM13GK8	Asthma	CA23	Discontinued in Phase 1	[14]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[15]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[12]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[16]
butaprost (free acid form)	DM5MZHP	Discovery agent	N.A.	Investigative	[15]
M&B 28767	DMJQG82	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin E2 receptor EP3 (PTGER3)	TTPNGDE	PE2R3_HUMAN	Modulator	[1]
Prostaglandin F2-alpha receptor (PTGFR)	TTT2ZAR	PF2R_HUMAN	Modulator	[1]

References

• [1] IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
• [2] Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
• [3] PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
• [4] Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
• [8] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [9] Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
• [10] THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
• [11] Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003 Apr 15;371(Pt 2):443-9.
• [12] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [13] BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
• [14] Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
• [15] The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
• [16] Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.